Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Gastman

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Future Oncology (London, England)|January 30, 2019
Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profilingJohn T Vetto, Eddy C Hsueh, Brian R Gastman, et al.
Cancer Gene Therapy|December 25, 2023
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.
Journal for Immunotherapy of Cancer|November 30, 2025
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery CommitteeGeorge Coukos, Marco Donia, Brian R Gastman, et al.
The Journal of Experimental Medicine|November 22, 2021
A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patientsChuan Li, Yee Peng Phoon, Keaton Karlinsey, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Journal of Translational Medicine|July 28, 2023
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, et al.
Anticancer Research|January 9, 2021
Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit MetastasisTimothy D Smile, David X Xiong, Vamsi Varra, et al.
BMC Cancer|February 7, 2018
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patientsJonathan S Zager, Brian R Gastman, Sancy Leachman, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Future Oncology (London, England)|January 30, 2019
Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profilingJohn T Vetto, Eddy C Hsueh, Brian R Gastman, et al.
Cancer Gene Therapy|December 25, 2023
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.
Journal for Immunotherapy of Cancer|November 30, 2025
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery CommitteeGeorge Coukos, Marco Donia, Brian R Gastman, et al.
The Journal of Experimental Medicine|November 22, 2021
A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patientsChuan Li, Yee Peng Phoon, Keaton Karlinsey, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Journal of Translational Medicine|July 28, 2023
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, et al.
Anticancer Research|January 9, 2021
Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit MetastasisTimothy D Smile, David X Xiong, Vamsi Varra, et al.
BMC Cancer|February 7, 2018
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patientsJonathan S Zager, Brian R Gastman, Sancy Leachman, et al.
Pageof 9